New Haven-based Trevi Therapeutics has reported positive results in a trial of its drug Haduvio for treatment of prurigo nodularis, a chronic inflammatory skin disease.
Trevi CEO Jennifer Good said, “This positive trial in prurigo nodularis … further supports our belief that Haduvio could potentially benefit patients across a broad range of refractory chronic pruritic and cough conditions.”